Baicalein attenuates 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells. 2005

Hyun Jung Lee, and Yoo Hun Noh, and Do Yeon Lee, and Yong Sik Kim, and Kyung Yong Kim, and Yoon Hee Chung, and Won Bok Lee, and Sung Su Kim
Department of Anatomy and Cell Biology, College of Medicine, Chung Ang University, Dongjak-ku, Seoul, Republic of Korea.

It has been suggested that baicalein, a flavonoid obtained from the Scutellaria root, exerts a protective role on neurons against several neuronal insults. However, the protective mechanisms underlying this protective effect remain largely unknown. Our results indicate that baicalein protects SH-SY5Y cells, a dopaminergic neuronal cell line, from 6-hydroxydopamine (6-OHDA)-induced damage by the attenuation of reactive oxygen species (ROS). In order to determine the effects of baicalein on mitochondrial events, mitochondrial membrane potentials (deltapsim) and caspase cascades downstream of mitochondria were assessed. Baicalein inhibited the collapse of deltapsim, suggesting that baicalein reduces the mitochondrial dysfunction associated with 6-OHDA treatment. Baicalein also inhibited caspase-9 and caspase-3 activation, which can be triggered by mitochondrial malfunctions. Furthermore, baicalein induced a significant reduction in the level of phospho-JNK, which is known as an apoptotic mediator in 6-OHDA-induced neuronal cell death. Our results indicate that baicalein protects neurons from the deleterious effects of 6-OHDA via the attenuation of oxidative stress, mitochondrial dysfunction, caspase activity, and JNK activation.

UI MeSH Term Description Entries
D008564 Membrane Potentials The voltage differences across a membrane. For cellular membranes they are computed by subtracting the voltage measured outside the membrane from the voltage measured inside the membrane. They result from differences of inside versus outside concentration of potassium, sodium, chloride, and other ions across cells' or ORGANELLES membranes. For excitable cells, the resting membrane potentials range between -30 and -100 millivolts. Physical, chemical, or electrical stimuli can make a membrane potential more negative (hyperpolarization), or less negative (depolarization). Resting Potentials,Transmembrane Potentials,Delta Psi,Resting Membrane Potential,Transmembrane Electrical Potential Difference,Transmembrane Potential Difference,Difference, Transmembrane Potential,Differences, Transmembrane Potential,Membrane Potential,Membrane Potential, Resting,Membrane Potentials, Resting,Potential Difference, Transmembrane,Potential Differences, Transmembrane,Potential, Membrane,Potential, Resting,Potential, Transmembrane,Potentials, Membrane,Potentials, Resting,Potentials, Transmembrane,Resting Membrane Potentials,Resting Potential,Transmembrane Potential,Transmembrane Potential Differences
D008928 Mitochondria Semiautonomous, self-reproducing organelles that occur in the cytoplasm of all cells of most, but not all, eukaryotes. Each mitochondrion is surrounded by a double limiting membrane. The inner membrane is highly invaginated, and its projections are called cristae. Mitochondria are the sites of the reactions of oxidative phosphorylation, which result in the formation of ATP. They contain distinctive RIBOSOMES, transfer RNAs (RNA, TRANSFER); AMINO ACYL T RNA SYNTHETASES; and elongation and termination factors. Mitochondria depend upon genes within the nucleus of the cells in which they reside for many essential messenger RNAs (RNA, MESSENGER). Mitochondria are believed to have arisen from aerobic bacteria that established a symbiotic relationship with primitive protoeukaryotes. (King & Stansfield, A Dictionary of Genetics, 4th ed) Mitochondrial Contraction,Mitochondrion,Contraction, Mitochondrial,Contractions, Mitochondrial,Mitochondrial Contractions
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D009447 Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51) Neuroblastomas
D009474 Neurons The basic cellular units of nervous tissue. Each neuron consists of a body, an axon, and dendrites. Their purpose is to receive, conduct, and transmit impulses in the NERVOUS SYSTEM. Nerve Cells,Cell, Nerve,Cells, Nerve,Nerve Cell,Neuron
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013565 Sympatholytics Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here. Sympathetic-Blocking Agents,Sympatholytic,Sympatholytic Agent,Sympatholytic Drug,Sympatholytic Agents,Sympatholytic Drugs,Sympatholytic Effect,Sympatholytic Effects,Agent, Sympatholytic,Agents, Sympathetic-Blocking,Agents, Sympatholytic,Drug, Sympatholytic,Drugs, Sympatholytic,Effect, Sympatholytic,Effects, Sympatholytic,Sympathetic Blocking Agents

Related Publications

Hyun Jung Lee, and Yoo Hun Noh, and Do Yeon Lee, and Yong Sik Kim, and Kyung Yong Kim, and Yoon Hee Chung, and Won Bok Lee, and Sung Su Kim
July 2019, Biomolecules & therapeutics,
Hyun Jung Lee, and Yoo Hun Noh, and Do Yeon Lee, and Yong Sik Kim, and Kyung Yong Kim, and Yoon Hee Chung, and Won Bok Lee, and Sung Su Kim
January 2003, Redox report : communications in free radical research,
Hyun Jung Lee, and Yoo Hun Noh, and Do Yeon Lee, and Yong Sik Kim, and Kyung Yong Kim, and Yoon Hee Chung, and Won Bok Lee, and Sung Su Kim
March 2021, Biomedicines,
Hyun Jung Lee, and Yoo Hun Noh, and Do Yeon Lee, and Yong Sik Kim, and Kyung Yong Kim, and Yoon Hee Chung, and Won Bok Lee, and Sung Su Kim
December 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Hyun Jung Lee, and Yoo Hun Noh, and Do Yeon Lee, and Yong Sik Kim, and Kyung Yong Kim, and Yoon Hee Chung, and Won Bok Lee, and Sung Su Kim
October 2018, Neurochemical research,
Hyun Jung Lee, and Yoo Hun Noh, and Do Yeon Lee, and Yong Sik Kim, and Kyung Yong Kim, and Yoon Hee Chung, and Won Bok Lee, and Sung Su Kim
April 2010, Toxicology in vitro : an international journal published in association with BIBRA,
Hyun Jung Lee, and Yoo Hun Noh, and Do Yeon Lee, and Yong Sik Kim, and Kyung Yong Kim, and Yoon Hee Chung, and Won Bok Lee, and Sung Su Kim
January 2011, Brain research,
Hyun Jung Lee, and Yoo Hun Noh, and Do Yeon Lee, and Yong Sik Kim, and Kyung Yong Kim, and Yoon Hee Chung, and Won Bok Lee, and Sung Su Kim
January 2011, Neuroscience letters,
Hyun Jung Lee, and Yoo Hun Noh, and Do Yeon Lee, and Yong Sik Kim, and Kyung Yong Kim, and Yoon Hee Chung, and Won Bok Lee, and Sung Su Kim
December 2013, Neurochemistry international,
Hyun Jung Lee, and Yoo Hun Noh, and Do Yeon Lee, and Yong Sik Kim, and Kyung Yong Kim, and Yoon Hee Chung, and Won Bok Lee, and Sung Su Kim
June 2010, The Journal of nutritional biochemistry,
Copied contents to your clipboard!